Research Progress on RNA m⁶A Modification in Tumor Development and Immunotherapy

m6 A (N6-methyladenosine) refers to the methylation modification that is observed at the N6 position of adenosine and is the most prevalent epigenetic modification seen in eukaryotic mRNA. Disruptions in m6 A methylation can result in aberrant gene transcription and translation procedures, thereby facilitating the onset and progression of cancer. Recent investigations have indicated that m6 A methylation not only impacts tumor cell proliferation and inhibitory networks but also regulates tumor immunogenicity. The objective of this analysis is to investigate the pertinent mechanisms of m6 A regulatory factors in governing vital signaling pathways in tumors and elucidate how m6 A epigenetic modification controls the expression of immune checkpoints. By undertaking this, this study offers a fresh perspective on the role and mechanism of m6 A epigenetic modification in regulating tumor immune escape. Furthermore, the article emphasizes the potential and future direction of targeted combination immunotherapy strategies based on m6 A modification, which could enhance the effectiveness of immune checkpoint inhibitors.

CSTR: 32200.14.cjcb.2023.12.0010